Holen Sie sich die Stockscreener-App
6.71
2.04%
-0.14
Handel nachbörslich:
6.70
-0.010
-0.15%
Schlusskurs vom Vortag:
$6.85
Offen:
$6.98
24-Stunden-Volumen:
17,236
Relative Volume:
0.09
Marktkapitalisierung:
$455.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-159.39M
KGV:
-1.8954
EPS:
-3.5401
Netto-Cashflow:
$-105.22M
1W Leistung:
-6.68%
1M Leistung:
+14.51%
6M Leistung:
-35.91%
1J Leistung:
-52.58%
1-Tages-Spanne:
$6.655
$6.99
1-Wochen-Bereich:
$6.54
$7.40
52-Wochen-Spanne:
$4.77
$14.72
Abivax Adr Stock (ABVX) Company Profile
Vergleichen Sie ABVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
6.71 | 455.98M | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-12-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | Laidlaw | Buy |
| 2024-05-20 | Eingeleitet | BTIG Research | Buy |
| 2024-04-29 | Eingeleitet | Guggenheim | Buy |
| 2024-04-29 | Eingeleitet | Piper Sandler | Overweight |
| 2023-11-14 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Abivax Adr Aktie (ABVX) Neueste Nachrichten
Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors - GlobeNewswire Inc.
Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister
Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks
Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks
Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks
Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq
Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance
Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily
Sibanye Stillwater Limited ADR (SBSW) rating downgrades by HSBC Securities - Knox Daily
Quantum Corp (QMCO) Stock: A Closer Look at the Market Potential - The News Heater
Analyzing the Price-to-Earnings Ratio of Abivax ADR (ABVX) - The News Heater
Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater
Paylocity Holding Corp’s (PCTY) Stock: A Long-Term Performance Analysis - The News Heater
Perrigo Company plc (PRGO) Stock: A Closer Look at the Moving Averages - The News Heater
Analyzing the Price-to-Earnings Ratio of ICL Group Ltd (ICL) - The News Heater
Tectonic Therapeutic Inc (TECX) Stock: A Review of the Recent Movement - The News Heater
Healthcare Triangle Inc (HCTI) Stock: A Closer Look at the Market Potential - The News Heater
Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks - MSN
Abivax Initiates $150 Million ATM Program on Nasdaq - TipRanks
Abivax Reports Strong Q3 Financials and Clinical Progress - TipRanks
Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks
Abivax Reports Progress in Ulcerative Colitis Therapy - TipRanks
Abivax SA Details Financial Struggles and Advances - TipRanks
Abivax ADR receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Citi Appointed as Depositary Bank for Abivax SA’s ADR Program - Business Wire
Finanzdaten der Abivax Adr-Aktie (ABVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):